ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda taps Schrödinger for drug discovery

by Rick Mullin
July 31, 2017 | APPEARED IN VOLUME 95, ISSUE 31

Takeda Pharmaceutical has entered a multitarget research collaboration with Schrödinger, a computational science firm. In an effort led by Schrödinger, the Japanese drug firm will provide protein crystal structures to guide the in silico design of new chemical entities in areas of therapeutic interest. Takeda has the option to license compounds from Schrödinger, paying up to $170 million per compound as well as royalties on future sales.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment